Serdar Inci
  1. Associate

Dr. Inci is an associate in Davis Polk's Corporate Department, practicing in the London office. His practice focuses on advising corporate and investment banking clients on strategic corporate transactions and international securities offerings (debt and equity) including initial public offerings, follow-on offerings and other SEC registered deals, Rule 144A and Regulation S transactions and other private placements.

Work Highlights

Since joining Davis Polk in 2018, Dr. Inci has advised clients on a broad range of capital markets transactions, including:

DEBT OFFERINGS

Issuers

  • A leading U.K. medical technology company on its SEC-registered $1.0 billion notes offering
  • Ferguson on its $600 million Rule 144A and Reg. S notes offering
  • A leading German automobile manufacturer on various Rule 144A and Reg. S notes offerings, totaling U.S. $9 billion
  • The investment banking arm of a Scottish bank on the establishment of its $5 billion U.S. commercial paper program
  • A Swiss multinational healthcare company on the update of its $7.5 billion U.S. commercial paper program

Underwriters/Initial Purchasers

  • The initial purchasers on Anglo American's $1.0 billion Rule 144 and Reg. S notes offering
  • The initial purchasers on Fresenius Medical Care's $1.0 billion Rule 144A and Reg. S notes offering
  • The underwriters on Deutsche Bank's $500 million SEC-registered offering of subordinated Tier 2 notes
  • The underwriters on British American Tobacco's SEC-registered $2.4 billion notes offering
  • The underwriters on Oesterreichische Kontrollbank’s SEC-registered $1.5 billion notes offering
  • The underwriters on the $1.25 billion SEC-registered additional tier 1 notes offering by the largest bank in Germany
IPO'S AND OTHER EQUITY OFFERINGS

Issuers

  • Oncopeptides on its SEK 1.1 billion (approx. $130 million) private placement of new shares
  • Centogene on its $49 million follow-on offering
  • EQT on its $1.4 billion initial public offering on Nasdaq Stockholm
  • Xspray Pharma on its SEK 265 million private placement of new shares
  • SEAS-NVE on its DKK 5.4 billion (approx. $800 million) secondary block sale of shares in Ørsted
  • Centogene on its $56 million initial public offering on Nasdaq

Underwriters

  • The underwriters on Levere Holdings Corp.'s $250 million initial public offering
LIABILITY MANAGEMENT TRANSACTIONS
  • NatWest Group plc’s $1.9 billion cash tender offer 

Of Note

  • Visiting Scholar, Harvard Law School, Program on Corporate Governance, 2016-2017

Professional History

  • Davis Polk since 2018

Practice Focus

Bar Admissions

  • State of New York

Education

  • J.D., University of Cologne, 2014
    • Dean's Award for Academic Excellence
    • Third in Class
  • Ph.D., University of Cologne, 2017
    • Ph.D. Scholarship
    • Studienstiftung Scholarship
    • summa cum laude
    • Editor-In-Chief, Cologne Business Law Review
  • LL.M., Columbia Law School, 2018
    • DAAD Scholarship
    • Dr. Theo Waigel Scholarship
    • Dr. Walter Oppenhoff Scholarship
    • ERP-Scholarship (German Rhodes)
    • Senior Editor, Columbia Journal of European Law

Languages

  • German
  • French
  • Turkish